Physician profile
Madhavi Devaraju
NPI 1699969949
$4,522.83
in general payments reported to CMS, 2019-2025
27 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $1,035 · 2021: $707 · 2022: $405 · 2023: $335 · 2024: $514 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.46 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.58 | 2019-2025 | Qulipta |
| Novo Nordisk INC | $778.46 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $365.24 | 2019-2024 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $360.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $290.83 | 2019-2022 | |
| Amgen INC. | $204.24 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $171.63 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.59 | 2019-2022 | |
| Astellas Pharma US INC | $126.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $104.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $99.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.85 | 2019-2024 | Ofev |
| Pfizer INC. | $76.38 | 2019-2020 | |
| Exact Sciences Corporation | $73.33 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $55.88 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.60 | 2019-2021 | |
| Ibsa Pharma INC. | $45.94 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $39.52 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Allergan, INC. | $28.25 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $22.23 | 2023 | Quviviq |
| Phadia US INC. | $22.11 | 2022 | |
| Aytu Biopharma, INC. | $20.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.00 | 2022 | |
| Medicure Pharma INC. | $15.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.84 | 2023 | Nuzyra |
| Glaxosmithkline, LLC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Devaraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.